JS
Therapeutic Areas
GenSight Biologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| GS010 (lenadogene nolparvovec) | Leber Hereditary Optic Neuropathy (LHON) due to ND4 mutation | Phase 3 |
| GS030 | Retinitis Pigmentosa (RP) | Phase 1/2 |
| Preclinical Programs | Geographic Atrophy in Dry Age-Related Macular Degeneration (Dry-AMD) | Preclinical |
Leadership Team at GenSight Biologics
LR
Laurence Rodriguez
Chief Executive Officer
JE
Jan Eryk Umiastowski
Chief Financial Officer
DM
Dr. Magali Taiel
Chief Medical Officer
DS
Dr. Scott Jeffers
Chief Technical Officer
BR
Botond Roska
Scientific Co-Founder
DN
Dr. Nancy J. Newman
Presenter (Emory University) - Key Opinion Leader associated with trial data